Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

When to operate? ovarian cancer trial tests best time for surgery after chemo

NCT ID NCT03579394

Disease control Sponsor: ARCAGY/ GINECO GROUP Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients received standard carboplatin and paclitaxel chemo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Carboplatin and paclitaxel chemotherapy followed by interval debulking surgery
What this could lead to
If successful, this could help doctors decide the best timing for surgery after chemotherapy to improve how long patients stay free of ovarian cancer.
What could go wrong
This is a completed trial, but it only looked at timing of surgery, not a new drug. Results may not apply to all ovarian cancer types or stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

211 people

The number who actually took part.

Started

Oct 2018

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female patients ≥18 years. 2. Histologically confirmed epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma, high grade serous or endometrioïd, with the exception of mucinous, clear cell and carcinosarcoma histologies. 3. Performance status \< 2 (see Appendix 2). 4. Documented International Federation of Gynecologic Oncology (FIGO 2014, Appendix 1) stage IIIB-IIIC-IVa unsuitable for complete primary cytoreductive surgery (confirmed by open laparoscopy or by laparotomy \[not mandatory for stage IVA\]). 5. Patient must be judged resectable after 3 courses of Neoadjuvant chemotherapy 6. Adequate bone marrow, liver and renal function to receive chemotherapy and subsequently to undergo surgery: * White blood cells (WBC) \>3x109/L, absolute neutrophil count (ANC) ≥1,5x109/L, platelets (PLT) ≥100x109/L, hemoglobin (Hb) ≥9 g/dL, * Serum creatinine \<1.25 x upper normal limit (UNL) or creatinine clearance ≥ 30 mL/min according to Cockroft-Gault formula or to local lab measurement, serum bilirubin \<1.25 x UNL, AST(SGOT) and ALT(SGPT) \<2.5 x UNL. 7. Signed informed consent obtained prior to any study-specific procedures. 8. Patient affiliated to, or a beneficiary of, a social security category Exclusion Criteria: 1. Mucinous, clear cell , carcinosarcoma and low grade serous carcinomahistologies. 2. Synchronous or previous other malignancies within 3 years prior to starting study treatment, with the exception of adequately treated non-melanomatous skin cancer or carcinoma in situ (of the cervix or breast or other sites). 3. Patients with brain metastases, seizure not controlled with standard medical therapy, or history of cerebrovascular accident (CVA, stroke) or transient ischemic attack (TIA) or subarachnoid hemorrhage before 6 months from the enrollment on this study. 4. Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise the adherence to the protocol (including but not limited to impaired cardiac function or clinically significant cardiac diseases, active or uncontrolled infections, HIV-positive patients on antiretroviral therapy, uncontrolled diabetes, cirrhosis, chronic active or persistent hepatitis, impaired respiratory function requiring oxygen-dependence, serious psychiatric disorders). 5. Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer stage IIIB Ovarian cancer stage IIIC Ovarian cancer stage IV

Contacts and locations

Locations

  • CHU Grenoble-Alpes - Site Nord (La Tronche)

    Grenoble, 38043, France

  • CHU de BREST - Hôpital Cavale Blanche

    Brest, 29200, France

  • CHU de Limoges - Hôpital de la Mère et de l'Enfant

    Limoges, 87000, France

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre François Baclesse

    Caen, 14000, France

  • Centre Georges François Leclerc

    Dijon, 21079, France

  • Centre Hospitalier Universitaire Bretonneau

    Tours, 37000, France

  • Centre Hospitalier Universitaire Caen

    Caen, 14033, France

  • Centre Jean Bernard - Clinique Victor Hugo

    Le Mans, 72000, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63000, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Clinique Médico-chirurgicale CHARCOT

    Sainte-Foy-lès-Lyon, 69110, France

  • Groupe Hospitalier Pitié Salpétrière

    Paris, 75651, France

  • Gustave Roussy

    Villejuif, 94805, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Européen Georges Pompidou

    Paris, 75015, France

  • Hôpital Privé du Confluent

    Nantes, 44202, France

  • Hôpital René Huguenin, Institut Curie

    Saint-Cloud, 92210, France

  • Hôpital Saint-Joseph

    Marseille, 13008, France

  • Hôpital Simone Veil

    Eaubonne, 95602, France

  • Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers

    Poitiers, 86021, France

  • Hôpital du Scorff

    Lorient, 56100, France

  • ICA - Polyclinique Urbain V

    Avignon, 84000, France

  • ICM Val d'Aurelle

    Montpellier, 34298, France

  • ICO Centre René Gauducheau

    Saint-Herblain, 44805, France

  • Institut Bergonié

    Bordeau, 33076, France

  • Institut Claudius Regaud

    Toulouse, 31059, France

  • Institut Jean Godinot

    Reims, 51056, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.